Saima Zameer

Experienced Postdoctoral Fellow specializing in neurodegenerative diseases, particularly Parkinson’s disease, with expertise in molecular biology, immunohistochemistry, nanoformulation, and translational research. Proven track record in advanced molecular assays, animal models, and drug delivery systems. Committed to driving innovation in therapeutic development and bridging basic science with clinical applications.

• Society of Biological Psychiatry
• Society for Neuroscience (SfN)
• International Society for Neurochemistry (ISN)
• Indian Pharmaceutical Association (IPA)

1. Gut-Brain Axis in Parkinson’s Disease:

· Investigation of aggregation prone proteoforms of alpha-synuclein and gene abnormalities in the human appendix and its propagation to the CNS

· Evaluation of seed amplification assays (SAA) as diagnostic tools for prodromal PD.

2. Neurodegeneration and Nanoformulation

· Development of brain-targeted nanoparticles for drug delivery in Alzheimer’s disease models.

· Investigation of Mevalonate pathway modulation via repurposing of drugs to ameliorate AD-related pathology.

3. Neurological conditions and COVID-19

· Determining epigenetic alterations in COVID-19 patients linked to neurological dysfunctions.

4. Clinical Research and data analysis

· Investigation of the effect of postmortem interval on the brain metabolites in suicide decedents

☨Equal contribution

· Anis E☨, Zameer S☨, Wierenga, J, Li P☨, Sikora J, Gordevicius J, Boonen E, Schilthuis M, LeDuc R, Kordower JH, Abbasi AA, Thomas P, Pinho M, Pritzkow S, Soto C, Brundin P, Brundin L☨, Killinger BA☨ Aggregation-prone alpha-synuclein proteoforms and dysregulated molecular signatures in the vermiform appendix.

· S. Zameer, E. Anis, Q. Sha, M. L. Escobar Galvis, S. Khan, J. A. Steiner, M. Milčiūtė, I. Kerševičiūtė, M. Gabrielaite, J. Gordevicius, A. Pospisilik, N. Saiyed, S. F. Graham, P. Brundin8, L. Brundin*. 1. Whole genome-based DNA methylation profiling in COVID-19 patients reveals alterations in pathways linked to neurological dysfunction.

• Dr. Lena Brundin, Professor, Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA, Lena.Brundin@vai.org
• Dr. Patrik Brundin, Therapeutic Area Leader for Movement Disorders, pRED Neuroscience & Rare Diseases, Pharma Research and Early Development, Neuroscience and Rare Disorders, F.Hoffmann La-Roche AG, Basel, Switzerland, patrik.brundin@roche.com
• Dr. Mohd. Akhtar, Professor, Dept. of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India, makhtar_ph@jamiahamdard.ac.in
• Dr. Divya Vohora, Professor, Dept. of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India, dvohra@jamiahamdard.ac.in

Fellowships

· 2021: Research Associate fellowship, Indian Council of Medical Research (ICMR), New Delhi, India

· 2018 - 2020: Senior Research Fellowship, Council of Scientific & Industrial Research, Human Resource & Development Group, New Delhi, India

· 2016 - 2018: Fellowship for Pharmaceutical Medicine, Sun Pharmaceuticals Pvt Ltd, New Delhi, India

· 2013 - 2015: GPAT Scholarship, All India Council for Technical Education, New Delhi, India

Awards

· 2019: Best oral presentation in IBRO-APRC associated school on Advances in Molecular Neurobiology

· 2018: Best poster presentation award in the National Conference on Alternatives to Animal Experiments

· 2018: Best poster presentation award in National Conference on Pharmacovigilance, Pharmacoeconomics and Outcomes Research

· 2015: Best poster presentation award in the National Symposium on “New Horizons in Drug Discovery and Development

Travel awards

· 2019: Travel Award, Kenes Organization – World Congress of Neurology, Dubai, UAE

· 2019: IBRO-SfN Travel Award – Society for Neuroscience Meeting, Chicago, IL, USA

· 2019: IBRO-APRC Travel Award – Advanced School on Molecular Basis of Neuroinflammation Mediated Neurodegeneration, Banaras Hindu University, Varanasi, India

· 2019: IBRO-APRC Travel Award – Associated School on Advances in Molecular Neurobiology, Amarkantak, India

1. Waheed A., Zameer S., et al. (2022). Developed lyotropic liquid crystalline nanoparticles for Apigenin targeting skin cancer. Eur J Pharm Biopharm, 180:269-280.

2. Zameer S., Alam M., et al. (2020). Neuroprotective effects of alendronate in mice on high-fat diet. Brain Res Bull, 361:197-212.

3. Zameer S., Ali J., et al. (2020). Chitosan nanoparticles of alendronate for Alzheimer's brain delivery. J Drug Target, 29(2):199-216.

4. Sharma N., Zameer S., et al. (2019). Lacosamide effects on ethanol-induced behavior in mice. Pharmacol Rep, 71(5):804-810.

5. Zameer S., Kaundal M., et al. (2018). Alendronate's effects on neuroinflammation and behavior in Alzheimer’s model. Neurotoxicol, 70:122-134.

6. Zameer S., Vohora D. (2017). Aromatase inhibitors' impact on memory and hippocampal proteins in female mice. Pharmacol Rep, 69(6):1300-1307.